Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 30.73%
March 31, 2026 33.65%
December 31, 2025 32.71%
September 30, 2025 36.19%
June 30, 2025 34.35%
March 31, 2025 37.54%
December 31, 2024 33.81%
September 30, 2024 37.22%
June 30, 2024 37.06%
March 31, 2024 33.09%
December 31, 2023 36.92%
September 30, 2023 36.56%
June 30, 2023 35.83%
March 31, 2023 35.01%
December 31, 2022 33.26%
September 30, 2022 33.14%
June 30, 2022 33.25%
March 31, 2022 31.45%
December 31, 2021 32.86%
September 30, 2021 32.34%
June 30, 2021 35.51%
March 31, 2021 36.66%
December 31, 2020 36.32%
September 30, 2020 35.16%
June 30, 2020 36.53%
Date Value
March 31, 2020 36.42%
December 31, 2019 36.25%
September 30, 2019 34.57%
June 30, 2019 37.74%
March 31, 2019 38.41%
December 31, 2018 36.42%
September 30, 2018 37.52%
June 30, 2018 39.57%
March 31, 2018 40.30%
December 31, 2017 39.70%
September 30, 2017 40.26%
June 30, 2017 40.66%
March 31, 2017 38.83%
December 31, 2016 36.51%
September 30, 2016 38.34%
June 30, 2016 40.74%
March 31, 2016 36.88%
December 31, 2015 39.25%
September 30, 2015 42.01%
June 30, 2015 42.48%
March 31, 2015 38.55%
June 30, 2014 37.62%
March 31, 2014 31.01%
December 31, 2013 36.37%
September 30, 2013 37.98%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --
Johnson & Johnson 68.73%
Eli Lilly & Co. 85.78%

Gross Profit Margin (Quarterly) Related Metrics